Skip to main content
. 2018 May;365(2):227–236. doi: 10.1124/jpet.117.245118

Fig. 5.

Fig. 5.

IbTX reduces disease severity in the CIA rat model of RA. (A) Clinical scores of paw inflammation of rats with CIA treated with vehicle (black) or 0.5 mg/kg IbTX (gray) every other day starting at disease onset. Data are the mean ± S.E.M. (n = 12 rats per group). (B) Ex vivo invasiveness of FLSs from three healthy Lewis rats, three rats with CIA treated with vehicle, and three rats with CIA treated with 0.5 mg/kg IbTX through Matrigel-coated Transwell inserts. Data are the mean ± S.E.M. (n = 3 per group). (C) Example X-ray images of paws from rats with CIA treated every other day with vehicle (left) or IbTX (right) for 14 days after disease onset. (D) Hematoxylin/eosin staining (top) and safranin O/fast green staining (bottom) of tissue sections of paws from rats with CIA treated with vehicle (left) or IbTX (right). Arrowheads indicate areas of hyperplasia (hematoxylin/eosin) and cartilage erosions (safranin O/fast green). (E) Histology scoring of paw joints of rats with CIA treated with vehicle (white) or IbTX (gray). Data are the mean ± S.E.M. (n = 3 paws per group). *P < 0.05; **P < 0.01. Scale bar, 100 μm in (D).